Fact CheckerSign in

NCT07891975Completed

Modulatory Effects of Resveratrol Supplement Along With and Without Low Glycemic Index Diet Among Obese Patients With Diabetic Nephropathy

Resveratrol Supplement Along With and Without Low Glycemic Index Diet Among Obese Patients With Diabetic Nephropathy

Source: ClinicalTrials.gov · Last updated 23 Oct 2026

Brief summary (registry, in English)

This 12-week randomized controlled trial evaluated the effects of resveratrol supplementation with and without a low glycemic index (LGI) diet in obese patients with diabetic nephropathy. Resveratrol, particularly at the higher dose combined with an LGI diet, significantly improved anthropometric, hepatic, renal, and biochemical parameters, including BMI, liver enzymes, BUN, UPCR, serum uric acid, phosphorus, and albumin levels. These findings suggest that resveratrol may serve as an effective nutraceutical adjunct to dietary modification for improving renal and metabolic health in diabetic nephropathy patients.

Status (registry)
Completed
Study type
Interventional
Enrollment
102 (actual)
First submitted
28 Jun 2026
Start date
Jun 2025
Primary completion date
Aug 2025
Lead sponsor
University of Lahore
NCT number
NCT07891975

What you commit to

  • Study type: Interventional
  • Participants enrolled: 102
  • From Jun 2025 to the primary completion date, Aug 2025
  • 1 site in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Other illness

  • Allergic to resveratrol.
  • Liver failure (acute or chronic).
  • Uncontrolled hypertension (BP ≥140/90 mmHg).
  • Congestive heart failure.
  • History of malignancy.
  • Any systemic disease other than diabetes.
  • Active infection or rheumatological disorder.

Other

  • Bilateral renal artery stenosis.
  • Use of warfarin or other anticoagulants.

Who the study is looking for

  • Obese individuals - BMI ≥ 30.0 kg/m²
  • Individuals with Fasting Plasma Glucose (FPG) ≤130 mg/dL
  • Individuals with HbA1c ≤ 8% (≤64 mmol/mol).
  • Urine albumin-creatinine ratio (UACR) ≥30 mg/g
  • Serum creatinine ≤2 mg/dL.
  • Blood urea nitrogen (BUN) ≤ 20 mg/dL
  • Estimated GFR (eGFR) ≥ 60 ml/min
  • Inflammatory and stress biomarkers through TNF-α \> 8.1 pg/mL and C-Reactive Protein (CRP) \> 3 mg/L.
  • Liver function test markers, ALT \> 56 U/L, AST \> 40 U/L, ALP \> 147 U/L.
  • Lipid profile levels, TC ≥ 200 mg/dL, TG ≥ 150 mg/dL, LDL ≥ 100 mg/dL, HDL ≤ 40 mg/dL.

Age in the registry: 40 years to 60 years · Sex: All · Accepts healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (1)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
Sana Noreen
Coordinator of this site? Confirm its status		LahorePakistanUnknown status

This page is information, not medical advice. Discuss any trial with your doctor.